GH Research (NASDAQ:GHRS) Announces Earnings Results, Beats Expectations By $0.13 EPS

GH Research (NASDAQ:GHRS) announced its earnings results on Friday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13, FiscalAI reports.

GH Research Price Performance

Shares of GHRS traded up $0.47 during mid-day trading on Friday, hitting $18.96. 428,113 shares of the company’s stock were exchanged, compared to its average volume of 303,502. GH Research has a 52 week low of $12.04 and a 52 week high of $31.44. The company has a market cap of $1.30 billion, a PE ratio of -19.00 and a beta of 1.31. The company has a 50-day simple moving average of $22.48 and a 200 day simple moving average of $21.63.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Stifel Nicolaus set a $38.00 target price on shares of GH Research in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of GH Research in a report on Monday, August 10th. New Street Research set a $65.00 target price on GH Research in a report on Monday, August 10th. Finally, Needham & Company LLC lifted their price target on GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GH Research presently has an average rating of “Moderate Buy” and an average price target of $44.36.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.